ReviewCancer science2005
The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.
Review in Cancer science, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 119 citations in OpenAlex.
- [Successful selpercatinib treatment of metastatic medullary thyroid cancer carrying rare RET variant].Magyar onkologia · 2026Article
- RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.International journal of molecular sciences · 2026Review
- A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer.BMC cancer · 2024Article
- AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer.International journal of molecular sciences · 2022Article
- Anticancer Activity of Erianin: Cancer-Specific Target Prediction Based on Network Pharmacology.Frontiers in molecular biosciences · 2022Article
- The Role of Neurotrophic Factors in Pathophysiology of Major Depressive Disorder.Advances in experimental medicine and biology · 2021Article
- APE1 Promotes Pancreatic Cancer Proliferation through GFRα1/Src/ERK Axis-Cascade Signaling in Response to GDNF.International journal of molecular sciences · 2020Article
- Review
- Review
- Enhanced Anti-Cancer Effects of Conditioned Medium from Hypoxic Human Umbilical Cord-Derived Mesenchymal Stem Cells.International journal of stem cells · 2019Article
- EVOLUTION OF TARGETED THERAPIES FOR THYROID CARCINOMA.Transactions of the American Clinical and Climatological Association · 2019Article
- Drug resistance profiles of mutations in the RET kinase domain.British journal of pharmacology · 2018Article
- Targeted Therapy for Medullary Thyroid Cancer: A Review.Frontiers in oncology · 2017Review
- Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo.Laboratory investigation; a journal of technical methods and pathology · 2016Article
- Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.BMC cancer · 2015Article
- Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Radiation signatures in childhood thyroid cancers after the Chernobyl accident: possible roles of radiation in carcinogenesis.Cancer science · 2015Review
- KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer.Molecular cancer · 2014Article
- Article
- Sorafenib cardiotoxicity increases mortality after myocardial infarction.Circulation research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The RET proto-oncogene is responsible for the development of several human inherited and non-inherited diseases. Germline point mutations were identified in multiple endocrine neoplasia types 2A and 2B, and familial medullary thyroid carcinoma. More than 10 rearranged forms of RET, referred to as RET/PTC 1-9, ELKS/RET and RFP/RET, have been cloned from sporadic and radiation-associated papillary thyroid carcinomas. These mutations induced oncogenic activation of RET tyrosine kinase by different mechanisms. To date, various kinds of therapeutic approaches have been developed for the treatment of RET-associated cancers, including tyrosine kinase inhibitors, gene therapy with dominant negative RET mutants, and RNA interference to abrogate oncogenic mutant RET expression. RET and some signaling molecules that function downstream of RET could be potential targets for the development of selective cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.